Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Orexigen Therapeutic (OREX)

Orexigen Therapeutic (OREX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Orexigen Therapeutic 3344 N. TORREY PINES CT. SUITE 200 LA JOLLA CA 92037 USA

www.orexigen.com P: 858-875-8600

Description:

OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.

Key Statistics

Overview:

Market Capitalization, $K 4,212
Shares Outstanding, K 18,890
Annual Sales, $ 33,710 K
Annual Net Income, $ -24,520 K
Last Quarter Sales, $ 18,900 K
Last Quarter Net Income, $ -20,830 K
60-Month Beta 2.46
% of Insider Shareholders 13.30%
% of Institutional Shareholders 36.43%

Growth:

1-Year Return -92.12%
3-Year Return -99.72%
5-Year Return -99.63%
5-Year Revenue Growth 666.14%
5-Year Earnings Growth 19.31%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.35 on 11/13/17
Latest Earnings Date 05/08/18
Earnings Per Share ttm -10.51
EPS Growth vs. Prev Qtr 25.82%
EPS Growth vs. Prev Year -33.66%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 07/12/16

OREX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % -72.74%
Debt/Equity N/A
Price/Sales 0.06
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -3.83
Interest Coverage -2.11
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar